Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
5 evidence topics · 7 sources
Background second-generation H1 antihistamine at a stable regimen in the phase 3 trials
Live vaccines excluded within 30 days before screening in the phase 3 trials; inactivated vaccines allowed
Phase 3b long-term extension observation group: standard of care with at least second-generation H1 antihistamines
Phase 2 background H1 antihistamine and live vaccine exclusion within 2 months
Phase 1b add-on to H1 antihistamine alone or with H2 antihistamine or leukotriene receptor antagonist, with rescue antihistamines
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion). Rescue treatments were allowed up to maximum allowable doses: diphenhydramine 100 mg 4× daily (QID), hydroxyzine 50 mg QID, or H2 antihistamine 4× the recommended dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was limited by the small sample size and variation in drugs used for background urticaria treatment; however, patients had to be on a stable regimen prior to barzolvolimab administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote